![]() |
市场调查报告书
商品编码
1510695
2030 年亚太地区心臟移植市场预测 - 区域分析 - 按手术类型、类型和最终用户Asia Pacific Heart Transplant Market Forecast to 2030 - Regional Analysis - by Surgery Type, Type, and End User |
亚太心臟移植市场预计将从2022年的34.2568亿美元成长到2030年的77.3974亿美元。
不断增长的老年人口推动亚太心臟移植市场
老年人群容易罹患心血管疾病、骨科疾病、代谢失调和神经系统疾病等。据世界卫生组织称,到2050年,全球老龄化人口可能从2019年的约10亿增至约21亿。 中国和印度的人口均超过10亿,截至2020年,亚洲人口将超过45亿,占世界总人口的一半以上。亚裔人口预计为 4.14 亿,比 65 岁及以上的美国人 3.314 亿多出约 20%。到2050年,预计亚洲老年人口将超过9.23亿。因此,老年人口的成长以及心臟衰竭盛行率的增加推动了心臟移植市场的成长。
亚太心臟移植市场概况
亚太地区心臟移植市场分为中国、印度、日本、韩国、澳洲和亚太地区其他地区。预计亚太地区在预测期内将成为全球市场中复合年增长率最快的地区。该地区市场的成长归因于医疗保健对器官捐赠重要性认识的提高以及社交媒体行销的激增,以鼓励对器官捐赠的积极态度。此外,在预测期内,改善医疗基础设施和增加投资以提高製造能力预计将推动亚太地区心臟移植市场的发展。根据《BioMed Central》发表的一篇文章,中国 40% 以上的死亡归因于心血管疾病。此外,2019年,我国心血管疾病患者约1,2,033万人。快速的社会经济进步正在影响中国人口的生活方式,这反过来又增加了心血管疾病、心臟或血管疾病的机会,可能导致心臟衰竭。目前,心臟移植是治疗晚期心臟衰竭唯一众所周知的有效方法。然而,由于心臟捐赠者数量有限,中国每年仅进行约300例心臟移植手术。因此,由于心臟移植等待时间较长,患有心臟衰竭的人选择人工心臟移植。
亚太心臟移植市场收入及 2030 年预测(百万美元)
亚太心臟移植市场细分
亚太地区心臟移植市场按手术类型、类型、最终用户和国家进行细分。
根据手术类型,亚太心臟移植市场分为原位心臟移植和异位心臟移植。 2022年,原位心臟移植细分市场在亚太心臟移植市场中占据更大份额。
从类型来看,亚太心臟移植市场分为活体捐赠心臟和人工心臟。 2022年,供体活体心臟细分市场在亚太心臟移植市场中占据较大份额。
根据最终用户,亚太心臟移植市场分为医院、心臟中心等。 2022年,医院细分市场在亚太心臟移植市场中占据最大份额。
依国家/地区划分,亚太地区心臟移植市场分为中国、印度、韩国、日本、澳洲和亚太地区其他地区。 2022年,中国将主导亚太心臟移植市场。
Terumo Corp、Abbott Laboratories、SynCardia Systems LLC、BiVACOR Inc、BioVentrix Inc 和 LivaNova Plc 是亚太心臟移植市场上的一些领先公司。
表中的内容
The Asia Pacific heart transplant market is expected to grow from US$ 3,425.68 million in 2022 to US$ 7,739.74 million by 2030. It is estimated to grow at a CAGR of 10.7% from 2022 to 2030.
Growing Geriatric Population Boosts Asia Pacific Heart Transplant Market
The geriatric population is prone to CVDs, orthopedic disorders, metabolic disorders, and neurological disorders, among others. According to the WHO, the aging population across the world is likely to rise from ~1 billion in 2019 to ~2.1 billion by 2050. With China and India accounting for more than one billion people each, Asia's population surpassed 4.5 billion as of 2020, making up more than half of the world's total population. Asians were predicted to number 414 million, which is around 20% more than the 331.4 million Americans who are 65 years of age or older. By 2050, it is expected that Asia will have over 923 million elderly population. Hence, the growing elderly population, along with the increasing prevalence of heart failure, fuels the heart transplant market growth.
Asia Pacific Heart Transplant Market Overview
The Asia Pacific heart transplant market is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is expected to register the fastest CAGR in the global market during the forecast period. The market growth in this region is ascribed to the rise in healthcare awareness of the importance of organ donation and a surge in social media marketing to encourage a positive attitude toward organ donation. Additionally, advancing healthcare infrastructure and increasing investments to boost manufacturing capacities are projected to drive the Asia Pacific heart transplant market during the forecast period. According to an article published in BioMed Central, more than 40% of the deaths in China are attributed to CVDs. In addition, in 2019, about 120.33 million people suffered from CVDs in China. Rapid socioeconomic progress is impacting the lifestyle of the population in China, which, in turn, increases the chances of contracting CVDs, conditions of heart or blood vessels that may result in heart failure. At present, heart transplantation is the only well-known effective treatment for advanced heart failure. However, owing to the limited number of heart donors, only ~300 heart transplants are performed in China annually. Therefore, people suffering from heart failure opt for artificial heart transplants due to the long waiting list for heart transplantation.
Asia Pacific Heart Transplant Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Heart Transplant Market Segmentation
The Asia Pacific heart transplant market is segmented into surgery type, type, end user, and country.
Based on surgery type, the Asia Pacific heart transplant market is bifurcated into orthotopic heart transplantation and heterotopic heart transplantation. The orthotopic heart transplantation segment held a larger share of the Asia Pacific heart transplant market in 2022.
In terms of type, the Asia Pacific heart transplant market is bifurcated into donor live heart and artificial heart. The donor live heart segment held a larger share of the Asia Pacific heart transplant market in 2022. Further, artificial heart segment is categorized into ventricular assisted device and total artificial heart.
Based on end user, the Asia Pacific heart transplant market is segmented into hospitals, cardiac centres, and others. The hospitals segment held the largest share of the Asia Pacific heart transplant market in 2022.
Based on country, the Asia Pacific heart transplant market is segmented into China, India, South Korea, Japan, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific heart transplant market in 2022.
Terumo Corp, Abbott Laboratories, SynCardia Systems LLC, BiVACOR Inc, BioVentrix Inc, and LivaNova Plc are some of the leading companies operating in the Asia Pacific heart transplant market.
Table of Content